Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01217437




Registration number
NCT01217437
Ethics application status
Date submitted
7/10/2010
Date registered
8/10/2010
Date last updated
23/07/2021

Titles & IDs
Public title
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Scientific title
Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial
Secondary ID [1] 0 0
NCI-2011-02605
Secondary ID [2] 0 0
NCI-2011-02605
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Central Nervous System Neoplasm 0 0
Pineoblastoma 0 0
Recurrent Medulloblastoma 0 0
Recurrent Primitive Neuroectodermal Tumor 0 0
Refractory Medulloblastoma 0 0
Refractory Peripheral Primitive Neuroectodermal Tumor 0 0
Condition category
Condition code
Cancer 0 0 0 0
Children's - Brain
Cancer 0 0 0 0
Brain
Cancer 0 0 0 0
Children's - Other
Cancer 0 0 0 0
Sarcoma (also see 'Bone') - soft tissue
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Cancer 0 0 0 0
Other cancer types
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Bevacizumab
Treatment: Drugs - Irinotecan Hydrochloride
Treatment: Drugs - Temozolomide

Experimental: Arm I (temozolomide, irinotecan hydrochloride) - Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.

Experimental: Arm II (temozolomide, irinotecan hydrochloride, bevacizumab) - Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.


Other interventions: Bevacizumab
Given IV

Treatment: Drugs: Irinotecan Hydrochloride
Given IV

Treatment: Drugs: Temozolomide
Given PO
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Up to 5 years after enrollment
Secondary outcome [1] 0 0
Response
Timepoint [1] 0 0
Up to 12 cycles of therapy (11 months)
Secondary outcome [2] 0 0
Event-free Survival
Timepoint [2] 0 0
Up to 5 years after enrollment

Eligibility
Key inclusion criteria
- Medulloblastoma or PNET of childhood that has relapsed or become refractory to
standard chemotherapy; patients with pineoblastoma are eligible

- Patients must have had histologic verification of the malignancy at original diagnosis
or at the time of recurrence

- Patients must have clear residual disease, defined as tumor that is measurable in two
perpendicular diameters on magnetic resonance imaging (MRI) OR diffuse leptomeningeal
disease OR clear MRI evidence of disease that may not be measurable in two
perpendicular diameters

- All patients must have a brain MRI with and without gadolinium and a spine MRI with
gadolinium performed within 2 weeks prior to study enrollment

- Patients must have a Lansky or Karnofsky performance status score of >= 50%,
corresponding to Eastern Cooperative Oncology Group (ECOG) categories of 0, 1, or 2
(use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of
age)

- Patients must have a life expectancy of >= 8 weeks

- Patients must have experienced at least one and at most two relapses prior to study
enrollment; patients with primary refractory disease are eligible

- Patients must have fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study

- Myelosuppressive chemotherapy: Must not have received within 3 weeks of entry
onto this study (6 weeks if prior nitrosourea)

- Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy
with a biologic agent; at least 3 weeks for biologic agents with a long half
life, such as antibodies

- External beam radiation therapy (XRT): Must not have received craniospinal
radiotherapy within 24 weeks prior to study entry; the tumor designated as
"measurable" for protocol purposes must not have received radiation within 12
weeks prior to study entry); focal radiation to areas of symptomatic metastatic
disease must not be given within 14 days of study entry

- Stem cell transplant (SCT): For autologous SCT, >= 3 months must have elapsed
prior to study entry

- Study specific limitations on prior therapy:

- Patients must not have previously received bevacizumab, irinotecan,
temozolomide or other anti-vascular endothelial growth factor (VEGF)
inhibitor

- Patients must not be taking enzyme-inducing antiepileptic medicines within 1
week of study entry

- Patients must have recovered from any surgical procedure before enrolling on this
study:

- Patients with a major surgical procedure within 28 days prior to enrollment
should be excluded

- Patients with an intermediate surgical procedure within 14 days prior to
enrollment should be excluded

- For minor surgical procedures (including Broviac line or infusaport placement),
patients should not receive the first planned dose of bevacizumab until the wound
is healed and at least 7 days have elapsed

- There should be no anticipation of need for major surgical procedures during the
course of the study

- Examples of major, intermediate, or minor surgical procedures:

- Major procedures: Major craniotomy for tumor resection; organ
resection; bowel wall anastomosis; arteriovenous grafts; exploratory
laparotomy; thoracotomy

- Intermediate procedures: Ventriculoperitoneal (VP)-shunt placement;
stereotactic brain biopsy

- Minor procedures: Incision and drainage of superficial skin abscesses;
punch biopsy of skin lesions; superficial skin wound suturing; bone
marrow aspirate and/or biopsy; fine needle aspirations; Broviac line or
infusaport placement; paracentesis or thoracocentesis

- Please note: Lumbar punctures or placement of peripherally inserted central
catheter (PICC) lines are not considered minor procedures and may occur at any
time prior to or during therapy

- Hypertension must be well controlled (=< 95th percentile for age and height if patient
is =< 17 years) on stable doses of medication

- Concomitant medications restrictions:

- Growth factor(s): Must not have received within 7 days of entry onto this study

- Steroids: Patients who are receiving corticosteroids must be on a stable or
decreasing dose for at least 7 days

- Study Specific: Patients must not be currently taking nonsteroidal
anti-inflammatory drugs (NSAIDs), clopidrogel, dipyridamole or aspirin therapy >
81 mg/day

- Peripheral absolute neutrophil count (ANC) >= 1000/uL (must not have received
filgrastim [G-CSF] within the prior 7 days)

- Platelet count >= 100,000/uL (transfusion independent)

- Hemoglobin >= 8.0 gm/dL (may receive packed red blood cell [PRBC] transfusions)

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min OR
a serum creatinine based on age/gender as follows:

- =< 0.4 mg/dL (for patients aged 1 month to < 6 months)

- =< 0.5 mg/dL (for patients aged 6 months to < 1 year)

- =< 0.6 mg/dL (for patients aged 1 to < 2 years)

- =< 0.8 mg/dL (for patients aged 2 to < 6 years)

- =< 1 mg/dL (for patients aged 6 to < 10 years)

- =< 1.2 mg/dL (for patients aged 10 to < 13 years)

- =< 1.4 mg/dL (for female patients aged >= 13 years)

- =< 1.5 mg/dL (for male patients aged 13 to < 16 years)

- =< 1.7 mg/dL (for male patients aged >= 16 years)

- Urine protein should be screened by dipstick analysis; if protein >= 2+ on dipstick,
then urine protein creatinine (UPC) ratio should be calculated; if UPC ratio > 0.5,
24-hour urine protein should be obtained and the level should be < 1000 mg/24 hours
for patient enrollment

- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x
upper limit of normal (ULN) for age

- Central nervous system function defined as

- Patients with a seizure disorder may be enrolled if well-controlled and on
non-enzyme inducing anticonvulsants

- Adequate coagulation defined as

- International normalized ratio (INR)/prothrombin time (PT) =< 1.5 x upper limit
of normal
Minimum age
No limit
Maximum age
21 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with a serious or non-healing wound, ulcer, or bone fracture are not eligible
for this study

- Patients must not have a history of abdominal fistula, gastrointestinal perforation or
intra-abdominal abscess within 6 months prior to study entry

- Patients must not have a known bleeding diathesis or coagulopathy

- Patients must not have had significant vascular disease (eg, aortic aneurysm requiring
surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to
study entry

- Patients must not have a known thrombophilic condition (i.e. protein S, protein C or
antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation,
homocysteinemia or antiphospholipid antibody syndrome); testing is not required in
patients without thrombophilic history

- Patients must not have evidence of new CNS hemorrhage on baseline MRI obtained within
14 days prior to study enrollment

- Patients with a history of stroke, myocardial infarction, transient ischemic attack
(TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater
congestive heart failure within the past 6 months are not eligible

- Patients must not have serious and inadequately controlled cardiac arrhythmia

- Female patients who are pregnant are not eligible for this study

- Female patients who are breastfeeding are not eligible for this study unless they
agree not to breastfeed

- Female patients of childbearing potential must have a negative pregnancy test

- Sexually active patients of childbearing potential must agree to use an effective
method of contraception during the study and for at least 6 months after the
completion of bevacizumab therapy

- Patients with known hypersensitivity to Chinese hamster ovary cell products or other
recombinant human antibodies

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/11/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/06/2021
Sample size
Target
Accrual to date
Final
108
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA
Recruitment hospital [1] 0 0
John Hunter Children's Hospital - Hunter Regional Mail Centre
Recruitment hospital [2] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [3] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [4] 0 0
Royal Brisbane and Women's Hospital - Herston
Recruitment hospital [5] 0 0
Royal Children's Hospital-Brisbane - Herston
Recruitment hospital [6] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [7] 0 0
Princess Margaret Hospital for Children - Perth
Recruitment postcode(s) [1] 0 0
2310 - Hunter Regional Mail Centre
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4029 - Herston
Recruitment postcode(s) [5] 0 0
4101 - South Brisbane
Recruitment postcode(s) [6] 0 0
6008 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Delaware
Country [7] 0 0
United States of America
State/province [7] 0 0
District of Columbia
Country [8] 0 0
United States of America
State/province [8] 0 0
Florida
Country [9] 0 0
United States of America
State/province [9] 0 0
Georgia
Country [10] 0 0
United States of America
State/province [10] 0 0
Hawaii
Country [11] 0 0
United States of America
State/province [11] 0 0
Idaho
Country [12] 0 0
United States of America
State/province [12] 0 0
Illinois
Country [13] 0 0
United States of America
State/province [13] 0 0
Indiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Iowa
Country [15] 0 0
United States of America
State/province [15] 0 0
Kentucky
Country [16] 0 0
United States of America
State/province [16] 0 0
Louisiana
Country [17] 0 0
United States of America
State/province [17] 0 0
Maryland
Country [18] 0 0
United States of America
State/province [18] 0 0
Massachusetts
Country [19] 0 0
United States of America
State/province [19] 0 0
Michigan
Country [20] 0 0
United States of America
State/province [20] 0 0
Minnesota
Country [21] 0 0
United States of America
State/province [21] 0 0
Mississippi
Country [22] 0 0
United States of America
State/province [22] 0 0
Missouri
Country [23] 0 0
United States of America
State/province [23] 0 0
Nevada
Country [24] 0 0
United States of America
State/province [24] 0 0
New Hampshire
Country [25] 0 0
United States of America
State/province [25] 0 0
New Jersey
Country [26] 0 0
United States of America
State/province [26] 0 0
New Mexico
Country [27] 0 0
United States of America
State/province [27] 0 0
New York
Country [28] 0 0
United States of America
State/province [28] 0 0
North Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
North Dakota
Country [30] 0 0
United States of America
State/province [30] 0 0
Ohio
Country [31] 0 0
United States of America
State/province [31] 0 0
Oklahoma
Country [32] 0 0
United States of America
State/province [32] 0 0
Oregon
Country [33] 0 0
United States of America
State/province [33] 0 0
Pennsylvania
Country [34] 0 0
United States of America
State/province [34] 0 0
Rhode Island
Country [35] 0 0
United States of America
State/province [35] 0 0
South Carolina
Country [36] 0 0
United States of America
State/province [36] 0 0
Tennessee
Country [37] 0 0
United States of America
State/province [37] 0 0
Texas
Country [38] 0 0
United States of America
State/province [38] 0 0
Utah
Country [39] 0 0
United States of America
State/province [39] 0 0
Vermont
Country [40] 0 0
United States of America
State/province [40] 0 0
Virginia
Country [41] 0 0
United States of America
State/province [41] 0 0
Washington
Country [42] 0 0
United States of America
State/province [42] 0 0
Wisconsin
Country [43] 0 0
Canada
State/province [43] 0 0
Alberta
Country [44] 0 0
Canada
State/province [44] 0 0
British Columbia
Country [45] 0 0
Canada
State/province [45] 0 0
Manitoba
Country [46] 0 0
Canada
State/province [46] 0 0
Nova Scotia
Country [47] 0 0
Canada
State/province [47] 0 0
Ontario
Country [48] 0 0
Canada
State/province [48] 0 0
Quebec
Country [49] 0 0
Canada
State/province [49] 0 0
Saskatchewan
Country [50] 0 0
New Zealand
State/province [50] 0 0
Auckland
Country [51] 0 0
New Zealand
State/province [51] 0 0
Christchurch
Country [52] 0 0
Puerto Rico
State/province [52] 0 0
San Juan

Funding & Sponsors
Primary sponsor type
Government body
Name
National Cancer Institute (NCI)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized phase II trial studies how well giving temozolomide and irinotecan
hydrochloride together with or without bevacizumab works in treating young patients with
recurrent or refractory medulloblastoma or central nervous system (CNS) primitive
neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal
antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. It is not yet known whether temozolomide and
irinotecan hydrochloride are more effective with or without bevacizumab in treating
medulloblastoma or CNS primitive neuroectodermal tumors.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01217437
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Adam S Levy
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01217437